Description
While much of the industry’s attention in 2021 was focused on FDA decisions about COVID vaccines and related therapies, a total of 50 new drugs were approved in 2021, outpacing the 10-year average for FDA drug approvals. This session provides a broad overview of the drugs approved in 2021, which includes significant growth in monoclonal antibody approvals. This session is designed to be a cursory overview of new approvals, bringing forward the most actionable and relevant pieces for those practicing in today’s pharmacies. The session includes a look at the COVID related emergency use authorizations and approvals introduced in 2021 and reviews some of the more controversial decisions and challenges of the year.